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Triptolide (TP) is a biologically active diterpene triep-
oxide from the Chinese herb Tripterygium wilfordii
Hook f. Here, we identify and explore TAB1 as
the binding target of TP in macrophages by using
a comprehensive approach combining pull-down
assays, in vitro assessments, and pharmaceutical
and biological evaluation. We discover that TP in-
hibits TAK1 kinase activity by interfering with the
formation of the TAK1-TAB1 complex, and the bind-
ing affinity of TP to TAB1 correlates highly with the
inhibitory activity of TP against MAPK pathway acti-
vation in macrophages. We also find that the amino
acid sequence between positions 373 and 502 of
TAB1 is required for TP interaction. Our results sug-
gest that TP could be a selective small-molecule
inhibitor of the TAK1-TAB1 complex and that TAB1
could be a potential therapeutic target in inflamma-
tory disease.
INTRODUCTION
Extracts of the root of Tripterygium wilfordii Hook f (TWHf) have
been used in traditional Chinese medicine for the treatment of a
variety of inflammatory and autoimmune diseases, such as rheu-
matoid arthritis, systemic lupus, psoriatic arthritis, and Behcet’s
disease, and effectively prolongs allograft survival in organ trans-
plants (Chen, 2001). Triptolide (TP), a diterpene triepoxide, is one
of the major components of most functional extracts of TWHf
and has anti-inflammatory, immunosuppressive, anti-tumor,
and anti-fertility properties (Liu, 2011). Clinical trials of TP and
its derivatives have shown great promise in the treatment of
cancer and autoimmune diseases (Kiviharju et al., 2002; Ma
et al., 2007). Studies of the molecular mechanisms underlying
the diverse actions of TP have illustrated that TP can significantly
impact cell-fate decision inmany cell types (Chen et al., 2009; Liu
et al., 2012; Zhao et al., 2000), and some of the specific molec-
ular targets of TP have been identified (Leuenroth and Crews,
2005; Leuenroth et al., 2007; McCallum et al., 2007). One of
the most successful discoveries, recently reported by Titov
et al. (2011), indicated that TP covalently binds to human XPB
and inhibits its DNA-dependent ATPase activity in tumor cells,
thus offering a unified molecular mechanism for the diverse bio-
logical activities of TP.246 Chemistry & Biology 21, 246–256, February 20, 2014 ª2014 ElseMacrophages play a pivotal role in the initiation, maintenance,
and resolution of inflammation. Macrophages produce a wide
range of biologically active factors that participate in both bene-
ficial and detrimental outcomes of inflammation. When the
control mechanisms go awry, the inflammatory responses of
macrophages can result in persistent inflammation, tissue injury,
and eventually carcinogenesis (Nathan and Ding, 2010). Thera-
peutic interventions that target macrophages may provide new
ways to control inflammatory diseases (Fujiwara and Kobayashi,
2005). At present, many potential candidate drugs resolve
inflammation by deactivating macrophages, including resvera-
trol (Tsai et al., 1999), simvastatin (Leung et al., 2003), sulforaph-
ane (Heiss et al., 2001), and theophylline (Ito et al., 2002), and TP
is one such drug (Wu et al., 2006). The immunosuppressive effect
of TP on macrophages has been somewhat well characterized.
Bao et al. (2007) found that TP inhibits the production of pro-
inflammatory cytokines and eventually induces apoptosis in
macrophages. TP can inhibit the expression of the p40 gene at
the transcriptional level and thus cause functional inhibition in
inflammatory macrophages (Zhang and Ma, 2010). Premkumar
et al. (2010) found that TP treatment modulated the expression
of 22.5% of 195 immune signaling genes, including Toll-like re-
ceptors (TLRs); the authors hypothesized that TP can block early
signaling pathways of TLRs, suggesting that the inhibitory action
of TP is at the receptor and adaptor molecule levels. Additionally,
the TP analog LLDT-8 suppresses inflammatory macrophages
by reducing intracellular nitric oxide (NO) production and induc-
ible nitric oxide synthase expression (Zhou et al., 2006). How-
ever, the mechanisms by which TP regulates macrophage
function remain elusive. Above all, the identification of TP targets
to date may not fully explain how TP can inhibit the activation of
macrophages in the low-nanomolar range without affecting their
proliferation.
Transforming growth factor-b-activated kinase 1 (TAK1) is a
member of the mitogen-activated protein kinase kinase kinase
(MAPKKK) family, which participates in pro-inflammatory cellular
signaling pathways that are stimulated by transforming growth
factor-b (TGF-b) (Yamaguchi et al., 1995), interleukin-1 (IL-1)
(Ninomiya-Tsuji et al., 1999), tumor necrosis factor-a (TNF-a)
(Shin et al., 2009), or lipopolysaccharides (LPSs) (Lee et al.,
2000). TAK1 requires a protein activator, TAK1-binding protein
(TAB1), to induce its full activation (Shibuya et al., 1996). Ectopic
expression of TAB1, together with TAK1, induces autophosphor-
ylation of TAK1 and thereby activates TAK1 kinase in vitro (Kish-
imoto et al., 2000). Therefore, the TAK1-TAB1 complex plays
critical roles in MAPK inflammatory signaling pathways.
In the current study, we explore and identify TAB1 as a molec-
ular and functionally distinct target of TP in macrophages byvier Ltd All rights reserved
Figure 1. Identification of TAB1 as a TP-
Binding Protein Ex Vivo
(A) TP-binding proteins were pulled down from the
total cell lysate, which had been incubated with TP
(30 mM), resolved by SDS gel electrophoresis, and
visualized by silver staining.
(B) Anti-TAB1 and protein A/G agarose was used
to pull down the TAB1-binding molecules in the
lysate, which had been incubated with TP (15 mM)
or without TP. Then the complex of TAB1 and TP
was destroyed by methanol and sonication. The
existence of TP in this coimmunoprecipitation was
detected by ESI-MS.
(C) Western blot analysis using the anti-TAB1
antibody and the samples from (A) validates TAB1
as the TP target protein.
(D) TP and TAB1 were observed by confocal
microscopy. TP-mmc (15 mM)was added to Ana-1
cells (upper panel: bar, 5 mm; lower panel: bar,
8 mm), and TP-mmc (15 mM) with/without TP
(15 mM) was added to RAW 264.7 cells (middle
panel: bar, 50 mm) for 2 hr, followed by the addition
of anti-TAB1 antibody (upper and middle panels:
10 ml) or anti-caspase-1 (lower panel: 10 ml) and the
fluorescently labeled secondary antibody.
(E) TP dose-dependently and specifically protects
the target TAB1 from degradation by proteases
in vitro. Different doses of TP (30 mM, 0.030 mM) or
DMSO (0.1%) were added to the protein lysate
without protease inhibitors for 4 hr at 37C. The
levels of TAB1 and GAPDH in the sample were
determined by western blot. The numbers under
each western blotting band mean the grayscale
value of the band.
(F) The recombinant TAB1 or BSA was incubated
with DMSO, TP (1.2, 12 mM) for 18 hr at 4C and
then digested with subtilisin at room temperature
for 20 min. The reactions were stopped by adding
SDS loading buffer and boiling for 5 min. Samples
were separated by SDS-PAGE and stained with
Coomassie brilliant blue.
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TAB1: A Target of Triptolide in Macrophagesusing a comprehensive approach that combines pull-down
assays and in vitro assessments, such as molecular spectros-
copy methods and isothermal titration microcalorimetry (ITC),
as well as pharmaceutical and biological evaluations. We
discover that TP inhibits TAK1 kinase activity by preventing the
formation of the TAK1-TAB1 complex. Notably, the amino acid
sequence between positions 416 and 502 of TAB1 plays a major
role in the binding affinity of TAB1 for TP, whereas amino acids
373 to 416 of TAB1 may be the binding domain required for TP
interaction. Our study describes the precise mechanism by
which TP inhibits MAPK pathway activation in macrophages
and provides evidence for TAB1 as a potential therapeutic target
in inflammatory disease.
RESULTS
TP Binds to TAB1
Pull-down assays and unbiased chemical proteomics were
used to analyze and detect the proteins targeted by small
molecules directly from cell lysates (Walther and Mann, 2010).
To isolate TP-binding proteins, a monoclonal antibody against
TP was prepared by using the triptolide succinate (mTP) asChemistry & Biology 21, 246the hapten derivatives (details in the Supplemental Experi-
mental Procedures, available online). The binding curves in
Figure S1 indicate that our anti-TP antibody has substantial
affinity to TP in cell lines and in vitro and is therefore an effec-
tive tool for identifying TP-binding proteins. Next, coimmuno-
precipitation (coIP) with anti-TP and protein A/G agarose was
used to pull down the TP-binding proteins in macrophages
(Table S2). The specific band in the gel (Figure 1A) was excised,
and the proteins were identified by liquid chromatography LTQ-
Orbitrap mass spectrometry (LC-LTQ-Orbitrap-MS). Notably,
there were several proteins in the specific band, and the
intensity of TAB1 was the highest among them. Consistent
with this finding, coimmunoprecipitation and western blot using
anti-TAB1 antibody further confirmed TAB1 as one of the
binding proteins of TP (Figure 1C). To confirm the existence
of complex of TP and TAB1, we used anti-TAB1 and protein
A/G agarose to pull down the TAB1-binding molecules in
macrophages lysate that had been incubated with TP
(15 mM). The existence of TP in this coimmunoprecipitation
was detected by electrospray ionization mass spectrometry
(ESI-MS) (Figure 1B), which indicated the non-covalent bonds
between TP and TAB1.–256, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 247
Figure 2. Identification of Recombinant
TAB1 as a TP-Binding Protein In Vitro
(A) Expression and purification of TAB1-his in
bacteria. Lane A, load sample; lane B, flow-
through; lane C, wash with 20 mM imidazole; lane
D, elution with 50 mM imidazole; lane E, elution
with 100 mM imidazole; lane F, elution with
250 mM imidazole.
(B) ITC data for binding of TP to TAB1. The upper
panels show the raw data, and the lower panels
show the corresponding binding isotherm fitted
according to the ‘‘three binding site’’ model.
Reference titration of ligand into buffer was used
to correct for heat of dilution. The thermodynamic
parameters (K, DH, and DS) are indicated on the
right.
(C) Synchronous fluorescence spectrum of TAB1-
his (T = 290 K, pH 7.40), CTAB1-his = 0.36 mM, CTP =
0–7 mM, Dl = 15 nm (left panel), Dl = 60 nm (right
panel).
(D) Binding of TP to the deletion mutants of TAB1.
TP (30 mM) was incubated with cell lysates from
293T cells that were transfected with the mutants
of TAB1-FLAG-pCDNA3.1 plasmids. Immunopre-
cipitation using anti-TP and immunoblotting with
anti-FLAG were performed as in Figure 1C. Lanes
1, 3, 5, and 7, input; lanes 2, 4, 6, and 8, coIP
sample.
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TAB1: A Target of Triptolide in MacrophagesToobserve theactionof TP in livingcells, chemical probeswere
designed based on the structure-activity relationship of TP. We
first prepared a fluorescence-tagged TP probe by modifying the
hydroxyl group at position 14 of TP using the coumarin derivative
4-bromomethyl-7-methoxycoumarin, a compound that is often
used as a fluorescent label for compounds possessing a carbox-
ylic or hydroxyl group (Wolf and Korf, 1992). A compound, desig-
nated TP-mmc, was identified by ESI-MS and emitted green
fluorescence with emission maxima around 500 nm (Figures
S2A and S2B) in Ana-1 cells (Figure S2C). In addition, TP-mmc
showed low nanomolar IC50 values in Ana-1 (90 nM) and RAW
264.7 (147 nM) cell growth inhibition assays (Table S1). These
results confirm that this probe retained the biological activity of
TP and maintained substantial affinity to the TP-binding protein.
To verify complexation between TP and TAB1 in living cells,
we treated cell lines with TP-mmc (15 mM) for 2 hr and then
probed for endogenous TAB1 using an immunofluorescence
assay so that the localization of TP-mmc and TAB1 could be
monitored under fluorescence and confocal microscopy. The
merged color (yellow) in Figure 1D suggests colocalization of
TP and Tab-1, which is consistent the existence of the TP-TAB1
complex in both Ana-1 and RAW 264.7 cell lines. Furthermore,
the binding of TP-mmc to TAB1 was sensitive to competition
with unlabeled TP, as indicated by a decrease in the merged248 Chemistry & Biology 21, 246–256, February 20, 2014 ª2014 Elsevier Ltd All rights reservcolor (yellow) in the middle panel of
Figure 1D, implying a specific interaction
between TP and TAB1. Moreover, cas-
pase-1 as a cytoplasmic protein was
used to verify this specific binding. As it
shown in the lower panel of Figure 1D,
the caspase-1 protein failed to colocalize
with TP.Drug-target identification from total cell lysates by drug-
induced conformational changes is a technology that may be
generally useful for the identification and validationof drug targets
(Nishiya et al., 2009). The principle of this technology is shown in
the lower panel of Figure 1E. In brief, soluble whole-cell lysate
lackingprotease inhibitorswas incubatedwith variousconcentra-
tions of TP, followed by detection of TAB1 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) by western blot. Major
cellular proteinswerenot significantly affectedbyTP, as indicated
by the control GAPDH. In contrast, TAB1 steadily increased in a
TP-dependent manner (upper panel in Figure 1E), indicating that
TP protects TAB1 from degradation by endogenous proteases.
In Vitro Analysis of the Interaction between TP and TAB1
To characterize the TP-TAB1 complex in vitro, we first prepared
his6-tagged TAB1 by cloning, expression, and purification
methods. The recombinant his6-tagged TAB1 (termed TAB1-
his) was successfully expressed in bacteria and purified via
metal-affinity chromatography (Figure 2A). Subsequently, the
direct interaction between TP and TAB1-his at physiological
pH 7.43 was studied by DARTS, ITC, and molecular spectros-
copy methods.
To rule out the possibility that TP is inhibiting molecular
machinery that targets TAB1 for degradation, we carried outed
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TAB1: A Target of Triptolide in Macrophagesthe recently described DARTS assay in which binding of a small
molecule to a protein target imparts protein resistance to certain
bacterial proteases, such as thermolysin and subtilisin (Chen
et al., 2011). We digested recombinant TAB1-his with subtilisin
in the presence of increasing concentrations of TP or vehicle.
To demonstrate the specificity of the binding between TP and
TAB1, we also incubated BSA protein with TP as negative con-
trol. TP (12 mM) partly protected recombinant TAB1, but not
BSA, from subtilisin digestion, confirming the specificity of bind-
ing of TP and TAB1 (Figure 1F). Therefore, this result reinforces
our identification of TAB1 as the target of TP.
We have used qualitativemethod-ITC to analyze TAB1 binding
to TP at 298K. The binding affinity and binding stoichiometry of
TAB1 to TP can be obtained by three-site binding model fitting
of the integrated binding heat (shown in Figure 2B). The binding
affinity of a ligand can be classified into low binding affinity (Ka <
104 M1), moderate affinity range (Ka = 104108 M1), and high
affinity (Ka > 108 M1). In this context, the results of ITC experi-
ments suggest that the TAB1 presents three TP binding sites
with moderate binding affinity (Ka = 98,800103,000 M1).
Synchronous fluorescence spectroscopy can yield informa-
tion about the molecular environment in the vicinity of the chro-
mospheres (Hu et al., 2004). Synchronous fluorescence of TAB1
provided characteristic information about the tyrosine residues.
The Dl values (scanning interval, Dl = lem-lex) stabilized at
15 nm (left panel, Figure 2C). The fluorescence-quenching
spectra of TAB1-his at various concentrations of TP are shown.
TAB1 had a fluorescence emission band at 325 nm when the
excitation wavelength was fixed at 265 nm, whereas TP had
no intrinsic fluorescence. The fluorescence intensity of TAB1
decreased regularly with increasing TP concentration, indicating
that the microenvironment of the tyrosine residue of TAB1was
affected by TP binding. Synchronous fluorescence of TAB1-his
(Dl = 60 nm) yielded characteristic information about the
tryptophan residues. Changes in the intrinsic fluorescence inten-
sity of TAB1 arose upon the addition of small molecules to
TAB1. The synchronous fluorescence spectra of TAB1 at various
concentrations of TP are shown (right panel, Figure 2C). When
the excitation wavelength was fixed at 352 nm, TAB1 had a
strong fluorescence emission band at 412 nm, whereas TP
had no intrinsic fluorescence. The fluorescence intensity of
TAB1 increased regularly, and a slight redshift of the emission
wavelength was observed with increasing TP concentration,
indicating that hydrophobicity around tryptophan residues
decreased in presence of TP. The redshift effect might suggest
that TP bound to the hydrophobic cavity of TAB1 resulted in
the loose structure of TAB1 and the polarity around the trypto-
phan residues was increased, whereas the hydrophobicity was
decreased (Sarkar et al., 2013). These results reflect the fact
that the microenvironment of the tryptophan residue was sub-
stantially affected by TP binding.
The Determination of Amino Acid Sequences in TAB1
Required for TP Binding
The above observations prompted us to investigate the binding
site for TP in the TAB1 protein. Only 68 C-terminal amino
acid residues of TAB1 are essential and sufficient for bind-
ing to TAK1 and for the induction of autophosphorylation/
activation of TAK1 (Ono et al., 2001). To map the TP interactionChemistry & Biology 21, 246region of TAB1, we made progressive deletions of TAB1 and
generated N-terminal TAB1 deletion mutants. N-terminal mu-
tants and wild-type TAB1 were labeled with the FLAG peptide
(DYKDDDDK) (Figure 2E). Mutants of TAB1 were constructed
using a eukaryotic expression plasmid (TAB1-FLAG-pCDNA3.1)
as described in the Supplemental Experimental Procedures.
To identify which FLAG-labeled TAB1 mutants bound to TP, a
plasmid containing a deletion mutant or full-length TAB1 was
transfected into 293T cells, and anti-TP-Protein A/G agarose
pull-down assays were performed. Western blot analysis using
an anti-FLAG antibody revealed that full-length TAB1 (D502)
and the mutant TAB1 (D416) could be pulled down, indicating
that these proteins bound normally to TP (Figure 2B). However,
comparison of the band intensity in line of TAB1 (D416) and
full-length TAB1 (D502) revealed that TAB1 (D416) had much
lower binding affinity for TP. Furthermore, TAB1(D373) or
TAB1(D213), which contained a deletion of all amino acids
following amino acid 373 or 213, respectively, failed to bind
to TP (Figure 2E). Our experiments reveal that the region
between amino acids 416 and 502 of TAB1 plays an important
role in TP binding, whereas the region between residues 373
and 416 of TAB1may be the binding domain required for interac-
tion with TP.
TP Inhibits TAK1 Kinase Activity through Repression of
TAK1-TAB1 Complex Formation in Cells
Following the identification of TAB1 as the binding protein of TP,
we were interested in the mechanism by which TP carries out its
considerable immunosuppressive activities. Because TAB1 is a
specific interaction partner of TAK1 and activates TAK1 by
directly binding to its catalytic domain (Shibuya et al., 1996),
we explored whether TP affects TAK1-TAB1 complex formation
and TAK1 kinase activity. Immunoprecipitation and immunoblot-
ting analyses indicated that TAB1 and TAK1 formed a stronger
complex in macrophages derived from the LPS group relative
to the vehicle control (Figure 3A). The presence of TP decreased
LPS-induced TAK1-TAB1 complex formation when TAK1 and
TAB1 were present at endogenous levels (Figure 3A). As ex-
pected, TP decreased the phosphorylation of TAK1 at Thr 187
in the dose- and time-dependent manner, both in macro-
phage-like cell lines (Figure 3B) and in murine peritoneal macro-
phage (Figure S3C), which is necessary for TAK1 activation
(Sakurai et al., 2000), compared to the LPS group, which sug-
gests an inhibitory effect of TP on TAK1 kinase activity.
The above observations prompted us to study TAK1 kinase
activity directly. We utilized a TAK1 kinase assay kit to quantify
the kinase activity of endogenous TAK1 in macrophages. After
the cells were stimulated only with LPS, the TAK1 kinase activity
values were 189.3 ± 0.74 U/mg (mean ± SE) in Ana-1 and 108.4 ±
3.3 U/mg in RAW 264.7 cells (Figure 3E). Upon stimulation by TP
and LPS, the kinase activity of TAK1 was 70.86 ± 0.87 U/mg in
Ana-1 and 42.96 ± 6.32 U/mg in RAW 264.7 cells. These quanti-
tative results show that TP inhibited the kinase activity of TAK1
stimulated by LPS in macrophages by more than 50%.
Because TAK1 plays an important role in the regulation of both
the c-Jun N-terminal kinase (JNK) and p38 MAPK cascades by
phosphorylating and activating the MAPK kinases MKK4 and
MKK3/6 (Wang et al., 1997), we analyzed the phosphorylation
levels of downstream signal molecules to verify the reduction–256, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 249
Figure 3. TP Inhibits TAK1 Kinase Activity
through Repression of the TAB1-TAK1
Interaction in LPS-Induced Cell Lines
Ana-1 cells were pretreated with TP (30 nM or the
indicated concentrations) or DMSO for 12 hr or
indicated time, followed by exposure to 0.5 mg/ml
LPS for 4 hr. Negative control cell group is only
treated with DMSO. Then the whole-cell lysates
were prepared.
(A) TP reduces the LPS-induced endogenous
TAK1-TAB1 interaction in Ana-1 cells. Ana-1 cells
were pretreated with TP (30 nM) or DMSO for 1 hr,
followed by exposure to 0.5 mg/ml LPS for 2 hr.
Whole-cell lysates were subjected to immuno-
precipitation with an anti-TAB1 or anti-TAK1
antibody. Immunoprecipitates were analyzed by
western blot using an anti-TAK1 or anti-TAB1
antibody.
(B) The phosphorylation of TAK1 was inhibited by
different concentration of TP (7.5, 15, and 30 nM)
and at the different pretreatment time (0.5, 1, 2, 4,
8, 12, and 18 hr). Whole-cell lysates were sub-
jected to western blot analysis using an anti-TAK1
or anti-pTAK1 antibody.
(C) TP reduces phosphorylation of the TAK1
kinase substrate and signaling pathways down-
stream of TAK1/MAPK. Whole-cell lysates were
subjected to western blot analysis using anti-
MKK3/6, anti-pMKK3/6, anti-MKK4, anti-pMKK4,
anti-pp38, anti-p38, anti-p-JNK, anti-JNK, anti-p-
ERK1/2, anti-ERK1/2, anti-p-c-Jun, or anti-c-Jun
antibodies.
(D) TPsuppresses theDNA-bindingactivityofAP-1.
Nuclear proteins were extracted and subjected to
an EMSA to evaluate AP-1 activation as described
in the Supplemental Experimental Procedures.
(E) TP inhibits the kinase activity of TAK1. TAK1
kinase activity in each group was determined
using the cellular TAK1/TAB1 kinase activity assay
kit in accordance with the manufacturer’s instructions. Each bar represents averaged results, n = 3 biological replicates, assayed three times each; error bars,
SE. **p < 0.01; ***p < 0.001. The red numbers under each western blotting band mean the grayscale value of the band.
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TAB1: A Target of Triptolide in Macrophagesof TAK1 kinase activity by TP pretreatment. We pretreated Ana-1
cells or mouse peritoneal macrophages with TP and then stimu-
lated these cells with LPS to examine whether TP affects TAK1-
induced phosphorylation of MKK4 and MKK3/6, because these
MKKs are the direct substrates of TAK1 kinase (Kim et al., 2009).
As shown in Figure 3C or Figure S3C, the phosphorylation level
of both MKK4 and MKK3/6 decreased with TP pretreatment in
the LPS-induced cells.
As mentioned above, JNK and p38 are direct substrates of
MKK4 and MKK3/6, respectively (Raman and Cobb, 2003).
Therefore, we examined whether TP inhibits LPS-induced JNK
and p38 activation. Activated JNK and p38 were detected by
anti-phospho-JNK and anti-phospho-p38 antibodies, respec-
tively. LPS-dependent JNK and p38 activation were abrogated
by pretreatment with TP (Figure 3C). Because ERK1/2 is not
direct substrate of MKK4 andMKK3/6, we analyzed it as a nega-
tive control and identified that the phosphorylation of ERK1/2
was not reduced by TP (Figure 3C), which is also supported by
our previous study (Lu et al., 2012). When JNK is activated, it
can phosphorylate and activate c-Jun (Ser 63 and Ser 73). Acti-
vated c-Jun, in combination with c-Fos, forms the activator pro-
tein 1 (AP-1) early-response transcription factor (Wadgaonkar250 Chemistry & Biology 21, 246–256, February 20, 2014 ª2014 Elseet al., 2004), which coordinates the induction of many genes
encoding inflammatory mediators (Guha and Mackman, 2001).
We therefore tested the phosphorylation level of c-Jun and found
that it was also inhibited by TP. Together, these results indicate
that TP might exert its influence on the pro-inflammatory
signaling involved in c-Jun activation via the MAPK pathway
(Figure 3C).
The MAP kinases, including p38 and JNK, control the activa-
tion of the downstream nuclear transcription factor of AP-1
(Wadgaonkar et al., 2004). As a next step, we investigated the
effect of TP on AP-1 activities. Macrophages were treated with
LPS only, TP plus LPS, or TP only, and the nuclear extracts
from these cells were examined for AP-1 DNA-binding activity
by an electrophoretic mobility shift assay (EMSA). TP inhibited
AP-1 binding activity (Figure 3D), suggesting that TP is able to
downregulate the AP-1 transcription factor activity initiated by
LPS in Ana-1 cells and, in turn, repress the release of some
pro-inflammatory cytokines (Figure 5B). Together, the above
results suggest that TP inhibits the TAK1 signaling pathway at
TAK1 or downstream of TAK1, e.g., MKKs and MAPKs.
To demonstrate that the effects of TP are largely due to its
inhibition of TAB1, we preferred to analyze bioactivity of TPvier Ltd All rights reserved
Figure 4. The Antagonism of TAB1 to the
Biological Activity of TP
(A and B) The 293T cells that were transfected with
TAB1-FLAG-pCDNA3.1 plasmids were exposed
to TP (30 nM) and TNF-a (50 ng/ml), and thewhole-
cell lysates were prepared. (A) Overexpression of
TAB1 promotes the expression of pro-inflamma-
tory cytokines, which were inhibited by TP. The
expression of TNF-a, IL-1b, IL-6, and IL-10 mRNA
was measured by real-time PCR. (B) Over-
expression of TAB1 promotes phosphorylation of
TAK1 and signaling molecules downstream of
TAK1/MAPK, which had been inhibited by the
TP. The whole-cell lysates were subjected to
western blot analysis using anti-P-TAK1, anti-
TAK1, anti-pp38, anti-p38, anti-p-JNK, anti-JNK,
anti-MKK3/6, anti-pMKK3/6, anti-MKK4, and anti-
pMKK4 antibodies.
(C) Schematic diagram represents the mechanism
by which TP affects the cascade of signaling
events through targeting TAB1 in macrophages.
Each bar represents averaged results, n = 3 bio-
logical replicates, assayed three times each; error
bars, SE. **p < 0.01; ***p < 0.001. The numbers
under each western blotting band mean the
grayscale value of the band.
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TAB1: A Target of Triptolide in Macrophageswhen there were lots of endogenous TAB1 in the cells because
TP exhibits immunosuppressive activity through forming the
TP-TAB1 complex. We found that overexpression of TAB1 in
the cells could promote phosphorylation of TAK1, MKK4, p38,
JNK, and MKK3/6 (Figure 4B), in response to TNF-a stimulation,
which had been inhibited by the TP. Next, the inhibitory effect of
TP on the expression of TNF-a, IL-1b, and IL-6 mRNA was also
obstructed by the overexpressed TAB1, whereas the expression
of IL-10mRNAwas not affected here (Figure 4A). In other words,
excessive TAB1 can terminate the inhibition effect of TP on
the MAPK pathway through binding TP so that it significantly
(p < 0.01) blocks the anti-inflammatory effect of TP.
The TAK1-TAB1 Interaction Can Be Blocked by TP in
Inflammatory Mice
To verify whether TAK1 kinase activity is inhibited by the interac-
tion of TP and TAB1 in vivo, we first established an inflammatory
mousemodel involving mice sensitized to LPS by a conventional
method (Hammer et al., 2006). Animal welfare and experimental
procedures were carried out in strict accordance with the Guide
for the Care and Use of Laboratory Animals (The Ministry of
Science and Technology of China, [2006]-398) and the related
ethical regulations of our university. Next, the mice were divided
into TP-pretreated, DMSO-pretreated, and vehicle control
groups as described in the Supplemental Experimental Proce-
dures. As expected, the mice treated with LPS developed
piloerection, progressing to hunching and listlessness before
becoming severely moribund, which necessitated euthanasia
at 1 to 2 days for DMSO-pretreated mice, compared with 3 to
4 days for TP-pretreated mice because the symptoms of the
latter group were partially relieved (data not shown).
The peritoneal macrophages were isolated from each group
after stimulation for 4 hr with LPS or PBS. Cell extracts from
the peritoneal macrophages showed increased formation of
the TAK1-TAB1 complex in DMSO-pretreated mice comparedChemistry & Biology 21, 246to the vehicle control mice. However, the peritoneal macro-
phages from the TP-pretreated animals showed significant (p <
0.01) repression of TAK1-TAB1 complex formation (Figure 5A).
Western blot using anti-phospho antibodies (Figures 5B and
5C) also showed that the phosphorylation levels of MKK4,
MKK3/6, JNK, p38, and c-Jun were reduced by TP pretreatment
in the peritoneal macrophages from the TP-pretreated mice
compared to DMSO-pretreated mice. Taken together, these
data show that TP modulates MAPK inflammatory pathways
through the attenuation of TAK1-TAB1 complex formation in
cell lines and in mice.
TP Inhibits LPS-Induced Macrophage Activation and
Inflammatory Response
To evaluate the biological effects of TP on LPS-activated macro-
phages, we analyzed the signs of macrophage activation in
Ana-1 cells or in mouse peritoneal macrophages, such as
TNF-a, NO, IL-6, and IL-12 production and phagocytic activity
(Fujiwara and Kobayashi, 2005). In a short-term test, cells were
pretreated with TP for 18 hr and then exposed to 0.5 mg/ml
LPS for 412 hr. Given the toxicity of TP, we chose a dose of
TP that barely affects the proliferation of Ana-1 cells (Figure 6A).
The concentrations of IL-6 and NO from the culture supernatant
(p < 0.01) increased by LPS treatment were significantly inhibited
by TP in vitro (Figures 6B and S3A). At the same time, the phago-
cytic activity, which is part of the characteristic macrophage
response to infection, was also attenuated by TP-pretreatment
in Ana-1 cells (right panel, Figure 6B) and in mouse peritoneal
macrophages (Figure S3B). Based on these results, we conclude
that TP plays a role in the negative regulation of macrophage
activation.
We sought to verify these results in an in vivo system utilizing
the LPS-mediated inflammation mouse model described
above. Accumulation of LPS in macrophages results in their
activation and, consequently, the overproduction of several–256, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 251
Figure 5. TP Inhibits TAK1 Kinase Activity
through Repression of the TAB1-TAK1
Interaction In Vivo
Mice were injected with or without TP (100 mg/kg,
intraperitoneal [i.p.]) and then stimulated with
LPS (4 mg/kg, i.p.) after 18 hr. The animals were
euthanized at 4 hr after LPS injection. Mouse
peritoneal macrophages were isolated, and
whole-cell lysates were prepared. The ‘‘con’’
means negative control group.
(A) TP reduces the LPS-induced endogenous
TAK1-TAB1 interaction in vivo. Whole-cell lysates
were subjected to immunoprecipitation with
an anti-TAB1 antibody. Immunoprecipitates and
whole-cell lysates were analyzed by western blot
using an anti-TAK1 or anti-TAB1 antibody.
(B) TP inhibits phosphorylation of TAK1. Whole-
cell lysates were subjected to western blot anal-
ysis using an anti-TAK1 or anti-pTAK1 antibody.
(C) TP reduces phosphorylation of the TAK1
kinase substrate and affects signaling pathways
downstream of TAK1/MAPK. Whole-cell lysates were subjected to western blot analysis using anti-MKK3/6, anti-pMKK3/6, anti-MKK4, anti-pMKK4,
anti-pp38, anti-p38, anti-p-JNK, anti-JNK, anti-p-c-Jun, and anti-c-Jun antibodies.
Each bar represents averaged results, n = 3 biological replicates, assayed three times each; error bars, SE. **p < 0.01; ***p < 0.001.
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TAB1: A Target of Triptolide in Macrophagespro-inflammatory cytokines, which contribute to the pathogen-
esis of inflammation (Suzuki et al., 2009). As shown in Figure 6C,
the DMSO-pretreated mice demonstrate increased serum levels
of TNF-a, IL-6, IL-1b, and IL-12 compared to the vehicle control
mice. In contrast, the animals pretreated with TP (100 mg/kg)
show significant (p < 0.05) attenuation of LPS-induced pro-
inflammatory cytokine release in serum, including TNF-a, IL-6,
and IL-12, but not IL-1b. In contrast, the concentrations of
anti-inflammatory cytokines in serum, such as IL-4, were not
affected by TP pretreatment compared to DMSO pretreatment
(Figure 6C). These results indicate that TP inhibits inflammation
by suppressing the release of pro-inflammatory cytokines.
We next sought to further examine the effect of TP on perito-
neal macrophages using the mouse model described above.
By treating cells with fluorescence-labeled latex beads, we
were able to visualize and assess the phagocytic activity of the
macrophages. In this study, the peritoneal macrophages from
DMSO-pretreated mice phagocytosed an average of 12.91 ±
1.04 latex beads per cell, whereas those from TP-pretreated
mice phagocytosed an average of only 7.38 ± 0.84 latex beads
(Figure 6D). The inhibition of macrophage phagocytic activity
by TP might be accorded with the deactivation of p38 because
it is reported that p38 alpha is important for phagocytosis of bac-
teria by macrophages (Kang et al., 2008). Ultimately, because
the phagocytosis—like most other problems in biology—will
have to be analyzed as a complex system, rather than a linear
series of isolated enzymatic reactions, the specific of this internal
mechanism still needs further research.
DISCUSSION
Emerging evidence from investigations of natural products has
shown that many natural compounds are vital leads, probes,
and clinical drugs (Vera et al., 2011). It is becoming increasingly
important to closely evaluate the relationship between the func-
tions and mechanisms of action of these biologically active mol-
ecules. Natural products exert pleiotropic effects and interfere252 Chemistry & Biology 21, 246–256, February 20, 2014 ª2014 Elsewith intracellular functions by targeting certain intracellular mol-
ecules, such as actin, TrxR, TRAP1, NF-kB, and the proteasome
(Gersch et al., 2012). Titov et al. (2011) recently reported that TP
blocks RNAPII-mediated transcription via covalent binding to
XPB, which may explain the inhibitory effects of TP on transacti-
vation byNF-kB, p53, NF-AT, andHSF-1 in all cancer and T cells.
In addition, calcium channel polycystin-2 (Leuenroth and Crews,
2005) and dCTP pyrophosphatase 1 (DCTPP1) (Corson et al.,
2011) have also been identified as potential molecular targets
of TP. These findings demonstrate that the intracellular partners
of TP that underlie its precise biological functions are multiple
and complex.
TP largely affects macrophage function and has been impli-
cated in non-resolving inflammation and the etiology of multiple
immune diseases, yet there have been no reports about the
potential targets of TP in macrophages, which is also the main
cell target of TP in clinical therapy. Here, we investigated the
target proteins of TP in macrophages by using a combined
approach that included pull-down assays, in vitro assessments,
and pharmaceutical and biological evaluation in both cell lines
and mice. The pull-down assay suggests that the non-covalent
bonds between TP and TAB1, which is very different from cova-
lent bonds between the TP and XPB (Titov et al., 2011). This
finding led us to identify the functional target TAB1 and discover
the role of TP in the interaction of TAB-1 and TAK1, as well as
their downstream signaling cascade in macrophages. Briefly,
upon macrophage activation, TP combines with TAB1, and this
interaction hinders TAK1-TAB1 complex formation. Conse-
quently, TAK1 kinase activity is inhibited by TP, as is the kinase
activity of the TAK1 kinase substrates MKK4 and MKK3/6. Next,
phosphorylation of p38 and JNK1/2 is affected, resulting in c-Jun
dephosphorylation and inhibition of AP-1 transcriptional activity.
The release of pro-inflammatory cytokines, such as TNF-a, IL-6,
and IL-12, is also downregulated and results in immune suppres-
sion (Figure 4E).
The final 86 C-terminal amino acids in TAB1 are important for
binding and activating TAK1, and their deletion affects thevier Ltd All rights reserved
Figure 6. TP Inhibits LPS-Induced Macro-
phage Activation and Inflammatory Re-
sponses
(A) Effects of TP on cell proliferation. Ana-1 cells
were treated with indicated concentrations of TP,
and cell proliferation was determined by MTT
proliferation assay.
(B) TP decreases NO, IL-6, and phagocytic activity
in LPS-induced Ana-1 cells. Ana-1 cells were
pretreated with the indicated concentrations of TP
for 12 hr and then exposed to 0.5 mg/ml LPS for
4 hr, except for NO assay. (Left panel) The con-
centration of IL-6 from the culture supernatant was
measured by ELISA. (Middle panel) NO production
was determined using an assay of the cell-free
culture supernatant (0.1 mg/ml LPS for 24 hr) for
nitrite and the Griess reagent. (Right panel)
The phagocytic activity of macrophages was
measured by the neutral red uptake (NRU) assay.
Each value represents the mean ± SE of three
separate experiments.
(C) The effects of TP (100 mg/kg, i.p.) on TNF-a,
IL-6, IL-1b, IL-13, IL-12, and IL-4 production in the
serum in LPS-induced mice (4 mg/kg, i.p.). The
profile of cytokine release was determined using
commercially available ELISA kits.
(D) The effects of TP on the phagocytic ability of
peritoneal macrophages in LPS-induced mice
prepared as in (C). The phagocytic ability of peri-
toneal macrophages in each group was tested
using latex beads.
Each bar represents averaged results, n = 3 bio-
logical replicates, assayed three times each; error
bars, SE. **p < 0.01; ***p < 0.001.
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TAB1: A Target of Triptolide in Macrophagesinteraction with TAK1 (Shibuya et al., 1996). Accordingly, to
further map the region of interaction between TAB1 and
TP, we first deleted the 86 C-terminal amino acids of
TAB1 and analyzed its interaction with TP. The results show
that TP does not bind directly to the 86 C-terminal amino acids
of TAB1. But this region is required for the TP interaction
because D(416) already showed dramatically decreased bind-
ing affinity to TP (Figure 2E). Next, we made progressive
deletion mutants from the C terminus of TAB1. The binding
assay between TP and these TAB1 mutants showed that the
amino acid sequence between positions 373 and 418 of
TAB1 is responsible for its affinity to TP and is also required
for formation of the p38a-TAB1 complex (Ge et al., 2002). A
possible explanation for these results is that interaction of TP
and some amino acids between positions 373 and 418 of
TAB1 induces structural and conformational changes in the
TAK1-binding domain of TAB1 and disrupts the ability of
TAB1 to bind to TAK1 in macrophages. Furthermore, because
the major phosphorylation sites of TAB1 are Thr431 and
Ser438, we think, this binding of TP to TAB1 may be phosphor-
ylation independent. These data yield clues for the further study
of the binding/active domain of TAB1 and the TP-interacting
site of TAB1.Chemistry & Biology 21, 246–256, February 20, 2014TAK1 plays a central role in intracellular
signaling pathways involved in host re-
sponses to physiological and/or environ-mental stress signals during inflammation (Lee et al., 2000).
TAK1 controls multiple protein kinase cascades, including the
activation of MKK4/7-JNK and MKK3/6-p38MAPK and their
downstream events. TAK1 even affects NF-kB transcription
(Kim et al., 2009): the activation of the TAK1-TAB1 complex
induces phosphorylation of IKKa/b, resulting in dissociation of
the IkB/NF-kB complex and translocation of the activated
NF-kB p65 into the nucleus (Ge et al., 2002). A possible underly-
ing mechanism involves the inhibition of NF-kB activation by TP
(He et al., 2007; Nie et al., 2012).
SIGNIFICANCE
The results in our current study show that blockage of TAB1-
TAK1 complex activation by TP could be an alternate
pathway for NF-kB inhibition. We speculate that TP
might participate in an LPS-mediated IKK/NF-kB signaling
cascade that is dependent on TAB1-TAK1 interaction.
Because TAK1 kinase has non-redundant functions in the
signaling pathways of inflammatory and immune responses,
inhibition of TAK1 activity is a valid approach to reverse
inflammation. For example, RNAi-based therapy has been
used to target TAK1 in rheumatoid arthritis (Courties et al.,ª2014 Elsevier Ltd All rights reserved 253
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TAB1: A Target of Triptolide in Macrophages2008). Furthermore, TAK1 is a druggable target whose inhi-
bition enhances the efficacy of traditional cytotoxic agents
in breast cancer cells (Martin et al., 2007), increases chemo-
sensitization in pancreatic cancer (Melisi et al., 2009), and
induces apoptosis in lymphoma cell lines (Buglio et al.,
2012). Although most of these findings are based on RNAi
therapy and remain in pre-clinical phases, our findings sug-
gest that TP could be a potent and selective small-molecule
inhibitor of the TAK1-TAB1 complex. Based on the above,
we can further optimize and select the TP analogs to
improve its anti-inflammatory effect and eliminate the inter-
ference of other binding molecules, such as XBP and cal-
cium channel polycystin-2. Our results are expected to
contribute to the fundamental understanding of the effects
of TP and to provide an approach for inhibiting TAK1 activity,
both indirectly and appropriately.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
RPMI 1640 and the Dulbecco’s modified Eagle’s medium (DMEM) were
purchased from GIBCO. All chemicals were purchased from Sigma, unless
otherwise stated. Anti-mouse PE-caspase1 was purchased from BD
PharMingen. The antibodies of TAB1, p-TAK1, TAK1, p38, and p-p38 were
purchased from Cell Signaling. The antibodies of MKK3/6, p-MKK3/6,
MKK4, p-MKK4, c-Jun, and p-c-Jun were purchased from Bioworld Com-
pany. The antibodies of ERK and p-ERK were purchased from Santa Cruz
Biotechnology.
Pull-Down Assay to Identify TP-Binding Proteins
The TP, mTP, or vehicle control (con1, con2) group received, respectively, TP
(30 mM), mTP (30 mM), or DMSO in the whole-protein lysate from cells (600 mg).
The anti-TP antibody and 15 ml of protein A/G agarose were added to the TP,
mTP, and con1 groups, whereas the con2 group was treated with 1 ml of
mouse IgG (0.5 mg/ml) and 15 ml of protein A/G agarose. The beads containing
bound proteins were briefly centrifuged and washed with the same lysis
buffer. The proteins were eluted from the protein A/G agarose in SDS sample
buffer, boiled for 2 min, and separated by 10% SDS-PAGE prior to silver
staining. The protein in the specific band was excised and identified by
mass spectrometry.
Mass Spectrometry
The peptides extracted from these bands were analyzed in triplicate by on-
line LC-LTQ-Orbitrap-MS. Proteomics analysis of a protein sample was con-
ducted in accordance withs an established procedure (Cox and Mann,
2008). In brief, samples from the control or coupling gel were separated by
12.5% SDS-PAGE and stained with Coomassie Brilliant blue R-250. Protein
bands that coprecipitated with TP were excised. Excised gel bands were
cut into small pieces and destained in 25 mM NH4HCO3 and 50% acetonitrile,
dehydrated with acetonitrile, and dried. The dried gel pieces were reduced
with a 10 mM DTT/25 mM NH4HCO3 solution and alkylated using a 55 mM
iodoacetamide/25 mM NH4HCO3 solution. The dried gel pieces were rehy-
drated with a 5 ng/ml trypsin solution (in 25mMNH4HCO3) and incubated over-
night at 37C. Peptides were extracted three times with a solution containing
5% formic acid and 50% acetonitrile. Samples were dried by vacuum centri-
fugation and then analyzed by LC-LTQ/Orbitrap. RawMS files were processed
with MaxQuant software, and proteins were identified by searching peak list
files against the decoy International Protein Index mouse database (v. 3.46)
containing both forward and reverse protein sequences.
Detection of Labeled TP Binding to TAB1 in Cells
The 4-methyl-7-methoxycoumarin (‘‘br-Mmc’’) derivative of TP was prepared
by refluxing 5 mg of TP, 8.8 mg of Br-Mmc, and 0.05 g of solid K2CO3 in
2ml of acetone for 1 hr. The solution was filtered, and the solvent was removed
in vacuo. The residuewas crystallized repeatedly using appropriate solvents to254 Chemistry & Biology 21, 246–256, February 20, 2014 ª2014 Elseremove Br-Mmc. Preparative yields of the pure ester were between 20% and
50%. The purity of the Mmc derivative (named TP-mmc) was evaluated by
thin-layer chromatography. The structure of this compound (TP-mmc) was
confirmed by mass spectrometry (Figure S2A).
Ana-1 or RAW 264.7 cells at 70% confluency on coverslips were incubated
with TP-mmc (30 mM) for 2 hr and cultured for an additional 1 hr in probe-free
medium. The cells were fixed with 3.7% formaldehyde in PBS for 30 min. The
cells were then permeabilized with 0.5% Triton X-100 for 5 min, followed by
blocking with 10% FBS. The cells were incubated with anti-TAB1 antibody
and PI-conjugated anti-IgG antibody. The resulting sample was washed with
PBS, and imaging data were acquired by confocal laser scanning microscopy
(Olympus).
Construction of Expression Vectors for TAB1 Deletion Mutants
TAB1mutants were constructed by PCR-basedmutagenesis using the appro-
priate synthetic oligonucleotides and mouse TAB1 cDNA as a template. The
resulting FLAG-labeled fragments FLAG were inserted into the XbaI-BamHI
site or into the mammalian expression vector (pcDNA3.1). All mutations
were confirmed by sequencing. The TAB1 clones TAB1(D502), TAB1(D416),
TAB1(D373), and TAB1(D213) were obtained, comprising the regions (from
the N terminus) 1–502, 1–416, 1–373, and 1–213, respectively.
Statistical Analysis
Data were expressed as the mean ± SE. Statistical analysis was performed by
Student’s t test when only two value sets were compared, and one-way
ANOVA, followed by Dunnett’s test, was performed when the data involved
three or more groups. p < 0.05, p < 0.01, or p < 0.001 was considered statis-
tically significant and indicated by *, **, or ***, respectively. The gray values of
western blotting band were analyzed by ImageJ software.
Other Methods
For the remaining experimental procedures and a more detailed description of
the above procedures, see the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.12.009.
AUTHOR CONTRIBUTIONS
P.S. and Y.L. planned the project. L.L. contributed to experiments depicted in
Table S2. Y.Z. and Y.L. performed all other experiments. Y.L. and P.S. wrote
the paper. All authors discussed the results and commented on the
manuscript.
ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China
(project nos. 91013015 and 81001665), the Science Fund for Creative
Research Groups (no. 81121062), and the National Natural Science Founda-
tion of China (project no. 31070764).
Received: September 10, 2013
Revised: November 21, 2013
Accepted: December 2, 2013
Published: January 23, 2014
REFERENCES
Bao, X., Cui, J.,Wu, Y., Han, X., Gao, C., Hua, Z., and Shen, P. (2007). The roles
of endogenous reactive oxygen species and nitric oxide in triptolide-induced
apoptotic cell death in macrophages. J. Mol. Med. 85, 85–98.
Buglio, D., Palakurthi, S., Byth, K., Vega, F., Toader, D., Saeh, J., Neelapu,
S.S., and Younes, A. (2012). Essential role of TAK1 in regulating mantle cell
lymphoma survival. Blood 120, 347–355.vier Ltd All rights reserved
Chemistry & Biology
TAB1: A Target of Triptolide in MacrophagesChen, B.J. (2001). Triptolide, a novel immunosuppressive and anti-inflamma-
tory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk.
Lymphoma 42, 253–265.
Chen, Y.W., Lin, G.J., Chia, W.T., Lin, C.K., Chuang, Y.P., and Sytwu, H.K.
(2009). Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro
and in vivo. Oral Oncol. 45, 562–568.
Chen, T., Ozel, D., Qiao, Y., Harbinski, F., Chen, L., Denoyelle, S., He, X.,
Zvereva, N., Supko, J.G., Chorev, M., et al. (2011). Chemical genetics identify
eIF2a kinase heme-regulated inhibitor as an anticancer target. Nat. Chem.
Biol. 7, 610–616.
Corson, T.W., Cavga, H., Aberle, N., and Crews, C.M. (2011). Triptolide directly
inhibits dCTP pyrophosphatase. ChemBioChem 12, 1767–1773.
Courties, G., Seiffart, V., Escriou, V., Scherman, D., Hoffmann, A., Jorgensen,
C., Gross, G., and Apparailly, F. (2008). RNAi-based therapy to target TAK1 in
rheumatoid arthritis. Hum. Gene Ther. 19, 1169–1169.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide pro-
tein quantification. Nat. Biotechnol. 26, 1367–1372.
Fujiwara, N., and Kobayashi, K. (2005). Macrophages in inflammation. Curr.
Drug Targets Inflamm. Allergy 4, 281–286.
Ge, B.X., Gram, H., Di Padova, F., Huang, B., New, L., Ulevitch, R.J., Luo, Y.,
and Han, J.H. (2002). MAPKK-independent activation of p38alpha mediated
by TAB1-dependent autophosphorylation of p38alpha. Science 295, 1291–
1294.
Gersch, M., Kreuzer, J., and Sieber, S.A. (2012). Electrophilic natural products
and their biological targets. Nat. Prod. Rep. 29, 659–682.
Guha, M., and Mackman, N. (2001). LPS induction of gene expression in
human monocytes. Cell. Signal. 13, 85–94.
Hammer, M., Mages, J., Dietrich, H., Servatius, A., Howells, N., Cato, A.C.B.,
and Lang, R. (2006). Dual specificity phosphatase 1 (DUSP1) regulates a sub-
set of LPS-induced genes and protects mice from lethal endotoxin shock.
J. Exp. Med. 203, 15–20.
He, J.K., Yu, S.D., Zhu, H.J., Wu, J.C., and Qin, Z.H. (2007). Triptolide inhibits
NF-kappaB activation and reduces injury of donor lung induced by ischemia/
reperfusion. Acta Pharmacol. Sin. 28, 1919–1923.
Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., and Gerha¨user, C. (2001).
Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-
inflammatory mechanisms. J. Biol. Chem. 276, 32008–32015.
Hu, Y.J., Liu, Y., Wang, J.B., Xiao, X.H., and Qu, S.S. (2004). Study of the inter-
action between monoammonium glycyrrhizinate and bovine serum albumin.
J. Pharm. Biomed. Anal. 36, 915–919.
Ito, K., Lim, S., Caramori, G., Cosio, B., Chung, K.F., Adcock, I.M., and Barnes,
P.J. (2002). A molecular mechanism of action of theophylline: induction of his-
tone deacetylase activity to decrease inflammatory gene expression. Proc.
Natl. Acad. Sci. USA 99, 8921–8926.
Kang, Y.J., Chen, J., Otsuka, M., Mols, J., Ren, S., Wang, Y., and Han, J.
(2008). Macrophage deletion of p38alpha partially impairs lipopolysaccha-
ride-induced cellular activation. J. Immunol. 180, 5075–5082.
Kim, S.I., Kwak, J.H., Na, H.J., Kim, J.K., Ding, Y., and Choi, M.E. (2009).
Transforming growth factor-beta (TGF-beta1) activates TAK1 via TAB1-medi-
ated autophosphorylation, independent of TGF-beta receptor kinase activity in
mesangial cells. J. Biol. Chem. 284, 22285–22296.
Kishimoto, K., Matsumoto, K., and Ninomiya-Tsuji, J. (2000). TAK1 mitogen-
activated protein kinase kinase kinase is activated by autophosphorylation
within its activation loop. J. Biol. Chem. 275, 7359–7364.
Kiviharju, T.M., Lecane, P.S., Sellers, R.G., and Peehl, D.M. (2002).
Antiproliferative and proapoptotic activities of triptolide (PG490), a natural
product entering clinical trials, on primary cultures of human prostatic epithe-
lial cells. Clin. Cancer Res. 8, 2666–2674.
Lee, J., Mira-Arbibe, L., and Ulevitch, R.J. (2000). TAK1 regulates multiple pro-
tein kinase cascades activated by bacterial lipopolysaccharide. J. Leukoc.
Biol. 68, 909–915.
Leuenroth, S.J., and Crews, C.M. (2005). Studies on calcium dependence
reveal multiple modes of action for triptolide. Chem. Biol. 12, 1259–1268.Chemistry & Biology 21, 246Leuenroth, S.J., Okuhara, D., Shotwell, J.D., Markowitz, G.S., Yu, Z.H., Somlo,
S., and Crews, C.M. (2007). Triptolide is a traditional Chinese medicine-
derived inhibitor of polycystic kidney disease. Proc. Natl. Acad. Sci. USA
104, 4389–4394.
Leung, B.P., Sattar, N., Crilly, A., Prach, M., McCarey, D.W., Payne, H.,
Madhok, R., Campbell, C., Gracie, J.A., Liew, F.Y., and McInnes, I.B. (2003).
A novel anti-inflammatory role for simvastatin in inflammatory arthritis.
J. Immunol. 170, 1524–1530.
Liu, Q. (2011). Triptolide and its expandingmultiple pharmacological functions.
Int. Immunopharmacol. 11, 377–383.
Liu, J., Shen, M., Yue, Z., Yang, Z., Wang, M., Li, C., Xin, C., Wang, Y., Mei, Q.,
and Wang, Z. (2012). Triptolide inhibits colon-rectal cancer cells proliferation
by induction of G1 phase arrest through upregulation of p21. Phytomedicine
19, 756–762.
Lu, Y., Bao, X., Sun, T., Xu, J., Zheng, W., and Shen, P. (2012). Triptolide atten-
uate the oxidative stress induced by LPS/D-GalN in mice. J. Cell. Biochem.
113, 1022–1033.
Ma, J., Dey, M., Yang, H., Poulev, A., Pouleva, R., Dorn, R., Lipsky, P.E.,
Kennelly, E.J., and Raskin, I. (2007). Anti-inflammatory and immunosuppres-
sive compounds from Tripterygium wilfordii. Phytochemistry 68, 1172–1178.
Martin, S.E., Pommier, Y., and Caplen, N.J. (2007). RNAi screening identifies
TAK1 as a potential target for the enhanced efficacy of traditional cytotoxic
agents in breast cancer cells. Mol. Cancer Ther. 6, 3331s–3331s.
McCallum, C., Kwon, S., Leavitt, P., Shen, D.M., Liu, W., and Gurnett, A.
(2007). Triptolide binds covalently to a 90 kDa nuclear protein. Role of epox-
ides in binding and activity. Immunobiology 212, 549–556.
Melisi, D., Xia, Q., Abbruzzese, J.L., and Chiao, P.J. (2009). TGF-beta-acti-
vated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic
cancer chemoresistance. JOP 14 (Suppl 5 ), 87.
Nathan, C., and Ding, A. (2010). Nonresolving inflammation. Cell 140, 871–882.
Nie, J., Zhou, M., Lu¨, C., Hu, X., Wan, B., Yang, B., and Li, Y. (2012). Effects of
triptolide on the synaptophysin expression of hippocampal neurons in the AD
cellular model. Int. Immunopharmacol. 13, 175–180.
Ninomiya-Tsuji, J., Kishimoto, K., Hiyama, A., Inoue, J., Cao, Z.D., and
Matsumoto, K. (1999). The kinase TAK1 can activate the NIK-I kappaB as
well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398,
252–256.
Nishiya, Y., Shibata, K., Saito, S., Yano, K., Oneyama, C., Nakano, H., and
Sharma, S.V. (2009). Drug-target identification from total cellular lysate by
drug-induced conformational changes. Anal. Biochem. 385, 314–320.
Ono, K., Ohtomo, T., Sato, S., Sugamata, Y., Suzuki, M., Hisamoto, N.,
Ninomiya-Tsuji, J., Tsuchiya, M., and Matsumoto, K. (2001). An evolutionarily
conserved motif in the TAB1 C-terminal region is necessary for interaction with
and activation of TAK1 MAPKKK. J. Biol. Chem. 276, 24396–24400.
Premkumar, V., Dey,M., Dorn, R., andRaskin, I. (2010).MyD88-dependent and
independent pathways of Toll-Like Receptors are engaged in biological activity
of Triptolide in ligand-stimulated macrophages. BMC Chem. Biol. 10, 3.
Raman, M., and Cobb, M.H. (2003). MAP kinase modules: many roads home.
Curr. Biol. 13, R886–R888.
Sakurai, H., Miyoshi, H., Mizukami, J., and Sugita, T. (2000). Phosphorylation-
dependent activation of TAK1 mitogen-activated protein kinase kinase kinase
by TAB1. FEBS Lett. 474, 141–145.
Sarkar, M., Paul, S.S., and Mukherjea, K.K. (2013). Interaction of bovine serum
albumin with a psychotropic drug alprazolam: Physicochemical, photophysi-
cal and molecular docking studies. J. Lumin. 142, 220–230.
Shibuya, H., Yamaguchi, K., Shirakabe, K., Tonegawa, A., Gotoh, Y., Ueno, N.,
Irie, K., Nishida, E., and Matsumoto, K. (1996). TAB1: an activator of the TAK1
MAPKKK in TGF-beta signal transduction. Science 272, 1179–1182.
Shin, M.S., Shinghirunnusorn, P., Sugishima, Y., Nishimura, M., Suzuki, S.,
Koizumi, K., Saiki, I., and Sakurai, H. (2009). Cross interference with TNF-
alpha-induced TAK1 activation via EGFR-mediated p38 phosphorylation of
TAK1-binding protein 1. Biochim. Biophys. Acta 1793, 1156–1164.
Suzuki, M., Tachibana, I., Takeda, Y., He, P., Minami, S., Iwasaki, T., Kida, H.,
Goya, S., Kijima, T., Yoshida, M., et al. (2009). Tetraspanin CD9 negatively–256, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 255
Chemistry & Biology
TAB1: A Target of Triptolide in Macrophagesregulates lipopolysaccharide-inducedmacrophage activation and lung inflam-
mation. J. Immunol. 182, 6485–6493.
Titov, D.V., Gilman, B., He, Q.L., Bhat, S., Low, W.K., Dang, Y.J., Smeaton, M.,
Demain, A.L., Miller, P.S., Kugel, J.F., et al. (2011). XPB, a subunit of TFIIH, is a
target of the natural product triptolide. Nat. Chem. Biol. 7, 182–188.
Tsai, S.H., Lin-Shiau, S.Y., and Lin, J.K. (1999). Suppression of nitric oxide syn-
thase and the down-regulation of the activation of NFkappaB in macrophages
by resveratrol. Br. J. Pharmacol. 126, 673–680.
Vera, B., Rodrı´guez, A.D., and La Clair, J.J. (2011). Aplysqualenol A binds to
the light chain of dynein type 1 (DYNLL1). Angew. Chem. Int. Ed. Engl. 50,
8134–8138.
Wadgaonkar, R., Pierce, J.W., Somnay, K., Damico, R.L., Crow, M.T., Collins,
T., and Garcia, J.G.N. (2004). Regulation of c-Jun N-terminal kinase and p38
kinase pathways in endothelial cells. Am. J. Respir. Cell Mol. Biol. 31, 423–431.
Walther, T.C., and Mann, M. (2010). Mass spectrometry-based proteomics in
cell biology. J. Cell Biol. 190, 491–500.
Wang,W.F., Zhou, G.S., Hu,M.C.T., Yao, Z.B., and Tan, T.H. (1997). Activation
of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated
c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta
(TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal
transduction. J. Biol. Chem. 272, 22771–22775.256 Chemistry & Biology 21, 246–256, February 20, 2014 ª2014 ElseWolf, J.H., and Korf, J. (1992). 4-Bromomethyl-7-methoxycoumarin and ana-
logues as derivatization agents for high-performance liquid chromatography
determinations: a review. J. Pharm. Biomed. Anal. 10, 99–107.
Wu, Y., Cui, J., Bao, X., Chan, S., Young, D.O., Liu, D., and Shen, P. (2006).
Triptolide attenuates oxidative stress, NF-kappaB activation and multiple
cytokine gene expression in murine peritoneal macrophage. Int. J. Mol.
Med. 17, 141–150.
Yamaguchi, K., Shirakabe, K., Shibuya, H., Irie, K., Oishi, I., Ueno, N.,
Taniguchi, T., Nishida, E., and Matsumoto, K. (1995). Identification of a mem-
ber of theMAPKKK family as a potential mediator of TGF-beta signal transduc-
tion. Science 270, 2008–2011.
Zhang, Y., andMa, X. (2010). Triptolide inhibits IL-12/IL-23 expression in APCs
via CCAAT/enhancer-binding protein alpha. J. Immunol. 184, 3866–3877.
Zhao, G., Vaszar, L.T., Qiu, D., Shi, L., and Kao, P.N. (2000). Anti-inflammatory
effects of triptolide in human bronchial epithelial cells. Am. J. Physiol. Lung
Cell. Mol. Physiol. 279, L958–L966.
Zhou, R., Zheng, S.X., Tang, W., He, P.L., Li, X.Y., Yang, Y.F., Li, Y.C., Geng,
J.G., and Zuo, J.P. (2006). Inhibition of inducible nitric-oxide synthase expres-
sion by (5R)-5-hydroxytriptolide in interferon-gamma- and bacterial lipopoly-
saccharide-stimulated macrophages. J. Pharmacol. Exp. Ther. 316, 121–128.vier Ltd All rights reserved
